BRIEF—EC approves Keytruda for six-week dosing schedule across all current monotherapy indications

The European Commission (EC) has approved Keytruda (pembrolizumab) for six-week dosing schedule across all current monotherapy indications.

This means that patients only need to attend hospital every six weeks rather than every three weeks, and will also help to reduce pressure on oncologists.

Keytruda, from US pharma giant Merck & Co, is already the world’s top-selling immuno-oncology drug.